The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 in combination with Gemcitabine in the Treatment of Patients with Advanced Pancreatic Cancer
- collapse A Prospective, Multicenter, Non-interventional Study to Evaluate Quality of Life in Chinese Postmenopausal HR(+) EBC Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
- collapse A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination with Liposomal Doxorubicin (Caelyx) in Patients with Advanced Solid Tumors
- collapse Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)
- collapse A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous Infusions of AZD9773 (CytoFab™) in Japanese Patients with Severe Sepsis and/or Septic Shock
- collapse An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
- collapse Epidemiologic study of KRAS mutation in Brazilian patients with advanced or metastatic Non Small Cell Lung Cancer.
- collapse An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cancer)
- collapse A phase I, randomised, 2 period cross over study to determine the comparative bioavailability of two different oral formulations of AZD2281 in cancer patients
- collapse A Phase I Open-Label Study to Assess the Safety and Tolerability of AZD2281(KU-0059436) in Combination with carboplatin (phase I), or in combination with a carboplatin/paclitaxel doublet (phase IIa), or in combination with paclitaxel (phase IIb) in the Treatment of Patients with Advanced Solid Tumours.
